Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk-Reference-Cited by-同舟云学术

Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk

Published:2015-12 Issue:52 Volume:94 Page:e2392
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Choi Ji-Young,Kang Yun-Jeong,Jang Hye Min,Jung Hee-Yeon,Cho Jang-Hee,Park Sun-Hee,Kim Yong-Lim,Kim Chan-Duck

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference31 articles.

1. Continuous renal replacement therapies for the treatment of acute renal failure in intensive care patients;Ronco;Clin Nephrol,1993

2. Continuous renal replacement therapies: an update;Manns;Am J Kidney Dis,1998

3. Anticoagulation for continuous renal replacement therapy;Tolwani;Semin Dial,2009

4. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage;van de Wetering;J Am Soc Nephrol,1996

5. Extracorporeal management of acute renal failure patients at high risk of bleeding;Ward;Kidney Int Suppl,1993

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How to safeguard the continuous renal replacement therapy circuit: a narrative review;Frontiers in Medicine;2024-08-21

2. Anticoagulation in Chronic Kidney Disease;Drugs;2024-08-09

3. The role of nafamostat mesylate anticoagulation in continuous kidney replacement therapy for critically ill patients with bleeding tendencies: a retrospective study on patient outcomes and safety;Kidney Research and Clinical Practice;2024-07-31

4. Organotypic lung tissue culture as a preclinical model to study host- influenza A viral infection: A case for repurposing of nafamostat mesylate;Tissue and Cell;2024-04

5. Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study;BMC Nephrology;2024-02-26